Table 3 Five-year overall survival and relapse-free survival of 69 patients who received Paclitaxel/Carboplatin
5y OS (95% CI) | P* | 5y RFS (95% CI) | P* | |
|---|---|---|---|---|
All patients (n = 69) | 87% (78–96) no of deaths: 7 | 79% (69–89) no of relapses: 14 | ||
Stage | .81 | .28 | ||
Ia, Ib (n = 16) | 94% (82–100) No of deaths: 1 | 93% (79–100) No of relapses: 1 | ||
Ic, II (n = 53) | 86% (75–97) No of deaths: 6 | 78% (66–90) No of relapses: 13 | ||
Grade | .88 | .30 | ||
1 (n = 12) | 92% (76–100) No of deaths: 1 | 92% (76–100) No of relapses: 1 | ||
2,3 (n = 54) | 86% (75–97) No of deaths: 6 | 78% (66–90) No of relapses: 13 | ||
Ia/Ib OR grade 1 (n = 28) | 93% (83–100) No of deaths: 2 | .58 | 92% (82–100) No of relapses: 2 | .03 |
Ic/II AND grade2/3 (n = 39) | 84% (71–97) No of deaths: 5 | 73%(58–88) No of relapses: 12 |